Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Market Closed
11 Aug, 06:57
XSHE XSHE Primary ¥
1. 52
+0.07
+4.83%
¥
7.16B Market Cap
- P/E Ratio
3.59% Div Yield
67,705,083 Volume
- Eps
¥ 1.45
Previous Close Day Range
1.36 1.52
Year Range
1.35 5.42
Want to track 000627 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
000627 closed today higher at ¥1.52, an increase of 4.83% from yesterday's close, completing a monthly increase of 2.01% or ¥0.03. Over the past 12 months, 000627 stock lost -67.52%.
000627 is not paying dividends to its shareholders.
The last earnings report, released on May 23, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
000627 Chart
Hubei Biocause Pharmaceutical Co., Ltd. Dividends
| 000627 30 May 2023 | Other | ¥0.11 Per Share |
| 000627 2 Jun 2022 | Other | ¥0.01 Per Share |
| 000627 4 Jun 2021 | Other | ¥0.01 Per Share |
| 000627 20 May 2020 | Other | ¥0.1 Per Share |
| 000627 26 Sep 2019 | Other | ¥0.03 Per Share |
Hubei Biocause Pharmaceutical Co., Ltd. Earnings
| 23 May 2025 Date | | - Cons. EPS | - EPS |
| 24 May 2024 Date | | - Cons. EPS | - EPS |
| 26 Oct 2016 Date | | - Cons. EPS | 0 EPS |
| 30 Aug 2016 Date | | - Cons. EPS | 0.01 EPS |
| 28 Apr 2016 Date | | - Cons. EPS | 0.19 EPS |
| 000627 30 May 2023 | Other | ¥0.11 Per Share |
| 000627 2 Jun 2022 | Other | ¥0.01 Per Share |
| 000627 4 Jun 2021 | Other | ¥0.01 Per Share |
| 000627 20 May 2020 | Other | ¥0.1 Per Share |
| 000627 26 Sep 2019 | Other | ¥0.03 Per Share |
| 23 May 2025 Date | | - Cons. EPS | - EPS |
| 24 May 2024 Date | | - Cons. EPS | - EPS |
| 26 Oct 2016 Date | | - Cons. EPS | 0 EPS |
| 30 Aug 2016 Date | | - Cons. EPS | 0.01 EPS |
| 28 Apr 2016 Date | | - Cons. EPS | 0.19 EPS |
Hubei Biocause Pharmaceutical Co., Ltd. (000627) FAQ
What is the stock price today?
The current price is ¥1.52.
On which exchange is it traded?
Hubei Biocause Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 000627.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 3.59%.
What is its market cap?
As of today, the market cap is 7.16B.
Has Hubei Biocause Pharmaceutical Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Hubei Biocause Pharmaceutical Co., Ltd. Profile
| Insurance - Life Industry | Financial Services Sector | Ms. Wenxia Zhou CEO | XSHE Exchange | CNE000000F48 ISIN |
| CN Country | 1,765 Employees | - Last Dividend | 12 Apr 2010 Last Split | 12 Nov 1996 IPO Date |
Overview
Hubei Biocause Pharmaceutical Co., Ltd. is a multifaceted enterprise based in Jingmen, China, with a primary focus on providing life and motor insurance products to the Chinese market. Beyond insurance, the company has diversified interests in the pharmaceutical, chemical, and new energy fuel sectors. The firm is engaged in both research and production activities across a variety of products and services. With an international footprint, Hubei Biocause Pharmaceutical exports its products to approximately 85 countries worldwide, including the United States and the European Union, showcasing its global reach and the diverse markets it serves.
Products and Services
- Life and Motor Insurance: Offering comprehensive insurance solutions tailored to meet the needs of individuals and families in China, the company provides essential financial protection against life's uncertainties.
- Pharmaceuticals: The company is actively involved in contract research and the production of APIs (Active Pharmaceutical Ingredients), intermediates, and various formulations such as tablets, granules, and capsules. These pharmaceutical products are designed to meet rigorous health and safety standards, addressing different therapeutic needs.
- Chemicals: Hubei Biocause Pharmaceutical provides a range of chemicals for industrial applications. This includes the manufacture of dimethyl ether gas, used as an aerosol propellant or a liquefied gas fuel, and a-chloropropionyl chloride, a key intermediate in organic synthesis.
- New Energy Fuels: In line with global sustainability efforts, the company invests in the new energy fuel sector, focusing on the development and production of cleaner, more efficient fuel alternatives to traditional fossil fuels.
Contact Information
Address: 122-132 Yangwan Road, Jingmen, China, 448000
Phone: 86 27 6565 1730
Website: https://www.biocause.com/
2025 © Marketlog. All Rights Reserved.
